Behavioral alterations in rotenone model of Parkinson's disease: Attenuation by co-treatment of centrophenoxine

Brain Research

Volumn 1201, Issue , 2008, Pages 122-127

  Nehru, Bimla ^a   Verma, Ranjeet ^a   Khanna, Pooja ^a   Sharma, Suresh Kumar ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Catalepsy; Centrophenoxine; Oxidative stress; Parkinson's disease; Rotenone

Indexed keywords

ANTIOXIDANT; DOPAMINE; MECLOFENOXATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; LIPID PEROXIDATION; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MUSCLE CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; LIPID PEROXIDATION; MALE; MECLOFENOXATE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; TREATMENT OUTCOME; UNCOUPLING AGENTS;

ANIMALIA; RATTUS;

EID: 40849146904     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.074     Document Type: Article

References (31)

1. Alam M., Mayarhofer A., and Schmidt W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav. Brain Res. 151 (2004) 117-124
2. Betarbet R., Sherer T.B., Mackenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
3. Bhalla P., and Nehru B. Modulatory effects of centrophenoxine in different regions of rat brain. Exp. Gerontol. 40 (2005) 801-806
4. Bishnoi M., Chopra K., and Kulkarni S.K. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur. J. Pharmacol. 552 (2006) 55-66
5. Bishnoi M., Chopra K.C., and Kulkarni S.K. Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol. Biochem. Behav. 88 4 (2007) 511-522
6. Church W.H. Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors. J. Undergrad. Neurosci. Educ. 3 (2005) A36-A41
7. Costall B., and Naylor R.J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34 (1974) 233-241
8. Fossati P., Galibert P., Lopez-pinto C., Pruvot P., Pruvot-brulin J., Arnott Laine E., and Linquette M. Centrophenoxine in the resuscitation of cranium-injured patients. Lille Med. 7 (1962) 500-506
9. Halliwell B., and Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci. 8 (1985) 22-29
10. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1956-1961
11. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 1 (1998) 24-34
12. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) 161-170
13. Kulisiewicz T.A. Evaluation of the effect of Lucidril (ANP 235, centrophenoxine) "Bracco" in some organic nervous diseases and in chronic alcoholism. Pol. Tyg. Lek. 28 20(26) (1965) 969-972
14. Kulkarni S.K. Handbook of Experimental Pharmacology. 3rd edn. (1999), Vallabh Prakashan, Delhi
15. Liao Y., Wang R., and Tang X.C. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol. Sin. 25 12 (2004) 1590-1596
16. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with Follin-phenol reagent. J. Biol. Chem. 193 (1951) 265-275
17. Ludolph A.C., He F., Spencer P.S., Hammerstad J., and Sabri M. 3-nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18 4 (1991) 492-498
18. Marcer D., and Hopkins S. The differential effects of meclofenoxate on memory loss in the elderly. Age and Aging 6 (1977) 123-131
19. Nehru B., Bhalla P., and Garg A. Evidence for centrophenoxine as a protective drug in aluminium induced behavioural and biochemical alteration in rat brain. Mol. Cell. Biochem. 290 (2006) 33-42
20. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology 40 (1990) 32-37
21. Samantaray S., Knaryan V.H., Guyton M.K., Matzelle D.D., Ray S.K., and Banik N.L. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146 2 (2007) 741-755
22. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J. Pineal Res. 42 3 (2007) 247-253
23. Schmidt W.J., and Alam M. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J. Neural Transm. Suppl. 70 (2006) 273-276
24. Sherer T.B., Richardson J.R., Testa C.M., Seo B.B., Panov A.V., Yagi T., Matsuno-Yagi A., Miller G.W., and Greenamyre J.T. Mechanism of toxicity of pesticides acting at complex 1: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100 6 (2007) 1469-1479 4
25. Sherer T.B., Betarberbet R., Tasta C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Yagi A.M., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 340 (2003) 0756-10764
26. Wills E.D. Mechanism of lipid peroxide formation in animal tissue. Biochem. J. 99 (1966) 667-676
27. Yong R., Liu R.W., Jiang H., Jiang Q., and Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280 40 (2005) 34105-34112
28. 2 release at mitochondria complex-1. J. Biol. Chem. 280 16 (2005) 15587-15594
29. Zs-Nagy I. A survey of the available data on a new nootropic drug, BCE-001. Ann. Y. Acad. Sci. 717 (1994) 102-114
30. Zs-Nagy I., and Semsei I. Centrophenoxine increases the rates of total and mRNA synthesis in the brain cortex of old rats: an explanation of its action in terms of the membrane hypothesis of aging. Exp. Gerontol. 19 3 (1984) 171-178
31. Zs-Nagy I., Pieri C., Giuli C., and Del Moro M. Effects of centrophenoxine on the monovalent electrolyte contents of the large brain cortical cells of old rats. Gerontology 25 (1979) 94-102